Koshinski Asset Management Inc. Purchases 210 Shares of Abbott Laboratories (NYSE:ABT)

Koshinski Asset Management Inc. increased its position in Abbott Laboratories (NYSE:ABT) by 0.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 24,745 shares of the healthcare product maker’s stock after purchasing an additional 210 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Abbott Laboratories were worth $2,799,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Intech Investment Management LLC increased its position in shares of Abbott Laboratories by 10.0% in the second quarter. Intech Investment Management LLC now owns 35,323 shares of the healthcare product maker’s stock worth $3,670,000 after purchasing an additional 3,200 shares during the period. Thrivent Financial for Lutherans grew its stake in Abbott Laboratories by 4.5% during the second quarter. Thrivent Financial for Lutherans now owns 479,241 shares of the healthcare product maker’s stock worth $49,799,000 after buying an additional 20,480 shares in the last quarter. Frank Rimerman Advisors LLC increased its holdings in Abbott Laboratories by 22,650.7% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 16,608 shares of the healthcare product maker’s stock valued at $1,726,000 after buying an additional 16,535 shares during the period. 1832 Asset Management L.P. raised its position in shares of Abbott Laboratories by 115.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 161,505 shares of the healthcare product maker’s stock valued at $16,782,000 after buying an additional 86,707 shares in the last quarter. Finally, Epoch Investment Partners Inc. boosted its position in shares of Abbott Laboratories by 1.7% during the 2nd quarter. Epoch Investment Partners Inc. now owns 60,703 shares of the healthcare product maker’s stock worth $6,308,000 after acquiring an additional 988 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $113.45 on Tuesday. Abbott Laboratories has a 1 year low of $99.71 and a 1 year high of $121.64. The firm’s 50-day moving average is $114.93 and its 200 day moving average is $112.87. The stock has a market cap of $196.78 billion, a price-to-earnings ratio of 34.48, a PEG ratio of 2.40 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a dividend yield of 2.08%. The ex-dividend date is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio is presently 66.87%.

Analysts Set New Price Targets

Several research firms have recently issued reports on ABT. Oppenheimer started coverage on Abbott Laboratories in a research note on Tuesday, October 8th. They issued an “outperform” rating and a $130.00 price objective for the company. Barclays raised their price target on shares of Abbott Laboratories from $143.00 to $149.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 17th. Raymond James reaffirmed a “buy” rating and set a $129.00 target price (up from $122.00) on shares of Abbott Laboratories in a report on Monday, October 14th. Finally, Sanford C. Bernstein increased their price target on Abbott Laboratories from $133.00 to $138.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $131.57.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.